Serum levels of fibroblast growth factor-23 and Klotho and their relation to kidney function deterioration in chronic kidney disease patients

Abstract

Objectives To analyze the relation of serum fibroblast growth factor-23 (FGF-23) and Klotho and their relation to the deterioration of kidney function in patients with chronic kidney disease (CKD). Methods 90 patients with CKD1 to CKD5 stages (CKD group) and 30 non-CKD patients (control group) were enrolled. Patients in CKD group were divided into deterioration of renal function group and stability of renal function group based on the annual decline rate of eGFR. The serum levels of FGF-23 and Klotho among all groups were determined by enzyme-linked immunosorbent assay (ELISA). The correlation of FGF-23 and Klotho and aggravation of renal function were analyzed. Results The level of FGF-23 in CKD group was significantly higher, while the level of Klotho was lower than that of control group. The characteristic changes in FGF-23 and Klotho were also detected as renal function progresses. The similar results were observed between groups of renal function deterioration and renal function stability. Pearson correlation analysis showed that serum FGF-23 in CKD patients was negatively correlated with Klotho. Conclusions FGF-23 levels in CKD patients would increase and Klotho levels would decrease when kidney function deteriorates. Serum FGF-23 and Klotho may be related to kidney dysfunction and can be used to predict CKD progression and poor prognosis in CKD patients. Key words: Kidney Diseases; Chronic Disease